Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008
p> patients. Preliminary data from this trial will be presented at the
American Society of Clinical Oncology meeting in June.
Genzyme is developing a new filing for the adult AML indication in
Europe. This follows its withdrawal of Bioenvision's marketing
application, which, as expected, an advisory committee deemed
insufficient to support approval. Genzyme expects to make a new
submission as early as the fourth quarter of this year that will
include a more robust data package from Genzyme sponsored studies.
Alemtuzumab for multiple sclerosis
-- Final, three-year efficacy and safety data from the Phase 2 trial
comparing alemtuzumab with Rebif (interferon beta-1a) for the treatment
of relapsing-remitting multiple sclerosis were presented last week
during a scientific platform session at the American Academy of
Neurology meeting by Dr. Alasdair Coles. These results confirm all
trends observed in the one- and two-year interim analyses. The two
ongoing Phase 3 trials further examining the efficacy and safety of
alemtuzumab for the treatment of MS are progressing. These two studies
are currently enrolling patients at sites in the United States, Europe,
Latin America and Australia. Genzyme believes that alemtuzumab has the
potential to be the best therapy in a market for MS drugs that is
projected to reach $8-9 billion annually when the treatment is expected
to be ready for launch in 2011-2012. Alemtuzumab is being developed in
collaboration with Bayer Schering Pharma AG, Germany.
Genz-112638 for Gaucher disease
-- Genzyme is making excellent progress in developing the small molecule
Genz-112638, a novel oral therapy intended for the treatment of Gaucher
disease. Initial results released one year ago for the first group of
stud
'/>"/>
| SOURCE Genzyme Corp. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
(Date:5/17/2013)... 17, 2013 Insero Health, Inc., a company developing ... and related neurological disorders, is today reporting top-line results ... INS001 in patients with drug-resistant epilepsy. The data are ... (AED) Xll meeting by Dr. Steven Schachter ... Insero,s Scientific Advisory Board. In this study, INS001 appeared ...
(Date:5/17/2013)... Rust removal is one of home maintenance's essential processes. Without ... To help rust contractors make it less expensive, My Cleaning ... it called Rusterizer. It announced that for this month, ... Cleaning Products explained that rust could damage items in two ... The first one, it said, happens when rust forms in ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 ... Barbara A. Myers, CAE, to the newly created ... her new role, Myers will be responsible for ... and production strategies, advancing the Society’s Member-led and ... and continuing to refine organizational, membership and product ...
(Date:5/16/2013)... Needham, Mass. (PRWEB) May 16, 2013 ... Bioprocessing Summit from August 19-23, 2013 at the Renaissance ... comprising the Summit provide a close-up look at the ... risk and ensuring bottom-line quality. Leaders in the ... innovative ways to produce biopharmaceuticals with greater specificity and ...
Breaking Biology Technology:Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2Organic-Based Rust Remover Cuts Down Price by 10%, My Cleaning Products Details Mechanics How to Get the Discount 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2[0] Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy[0] Organic-Based Rust Remover Cuts Down Price by 10%, My Cleaning Products Details Mechanics How to Get the Discount[0] ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development[0] The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA
... Sigma-Aldrich Corporation (Nasdaq: SIAL ) will be ... Monday, January 10th at 10:00 AM PT in San Francisco, ... the Internet available at http://investor.sigmaaldrich.com/ . Users can ... About Sigma-Aldrich: Sigma-Aldrich is a ...
... Communications Group, LLC will host a panel discussion dedicated ... financial as well as trade journalists. The event will ... San Francisco on Tuesday, January 11, 2011 from 8:00 ... on media interview preparation and understanding the differing needs ...
... 2011 Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) ... will be presenting at the 29th Annual J.P. Morgan Healthcare ... Francis Hotel in San Francisco. Mr. Bentsur,s presentation is scheduled ... PST (7:00 p.m. EST). A live audio webcast ...
Cached Biology Technology:Rx Communications Group to Host Panel Discussion for Biotechnology Executives on Communicating with the Media 2Rx Communications Group to Host Panel Discussion for Biotechnology Executives on Communicating with the Media 3Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference 2(Date:5/17/2013)... South, but the night belongs to the amphibians. In ... humidity and the sounds of wildlife. , The Southeast, ... salamanders, is the center of amphibian biodiversity in our nation. ... their symphonic choruses, the scientists of the U.S. Geological Survey,s ... , Amphibians, which rely on water for part ...
(Date:5/17/2013)... proteins in the brain responsible for protecting nerve cells ... increase cell survival. , The discovery, made by researchers ... the EMBO journal with additional comment in ... stroke and other brain diseases. , The research builds ... protein, known as SUMO, responsible for controlling the chemical ...
(Date:5/17/2013)... Dartmouth College study finds human-caused climate change may ... lizards, contradicting a host of recent studies that ... planet. , The findings, which appear in the ... hope for survival of a creature thought to ... that tropical cold-blooded animals, especially forest lizards, will ...
Breaking Biology News(10 mins):Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4SUMO wrestling cells reveal new protective mechanism target for stroke 2Climate change may have little impact on tropical lizards 2... the fittest affect every organism on Earth, even Monarch ... to parasite infections; scientists just uncovered why it is ... while migrating long distances, so they can't propagate the ... outcome of animal migration is whether these long journeys ...
... Mellon University scientists have "programmed" cells to make their ... gene expression. The results, appearing in the April issue ... studies in the emerging field of molecular therapeutics and ... , "For 20 years it has been the chemist's ...
... AFFX - News) and Karolinska Institutet announced today ... designed to improve healthcare by accelerating the translation ... diagnosis, prognosis, and treatment. , During the next ... measurement of gene expression in patients with atherosclerosis, ...
Cached Biology News:Carnegie Mellon scientists develop tool that uses MRI to visualize gene expression in living animals 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 3Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |